approach for women who experience abnormal uterine bleeding (AUB) who desire contraception and who are under anticoagulation therapy. Despite their meticulous citation of the literature, several important issues need further consideration.
In the past decade, direct-acting oral anticoagulants have emerged as alternatives to vitamin K antagonists in stroke prevention in atrial fibrillation as well as in the prevention and treatment of venous thromboembolism. 2 Four direct-acting oral anticoagulants are currently approved: rivaroxaban, apixaban, edoxaban (direct Factor Xa inhibitors), and dabigatran (direct thrombin inhibitor). 2 In contrast to vitamin K antagonists, direct-acting oral anticoagulants have few drug-drug interactions and more predictable pharmacokinetics. Further, direct-acting oral anticoagulants are administered in fixed doses, without the need for routine coagulation monitoring. Owing to the more convenient use of this drug class, gynecologists are increasingly likely to encounter women treated by these drugs in their routine practice. However, although direct-acting oral anticoagulants have been shown to reduce the incidence of major bleeding events compared with vitamin K antagonists, they have been reported to increase the risk of AUB. 3 It is worth noting that this increased risk is attributed to all three direct Factor Xa inhibitors, including apixaban and edoxaban, and not only rivaroxaban 4 ; in contrast to the claim by Bonnington and Autry. 1 Although unpractical with vitamin K antagonists, temporary dose reduction of direct-acting oral anticoagulants during the menstrual cycle may benefit women with AUB. 3 Alternatively, the use of dabigatran may be preferable in these patients. 3 Regarding the use of hormonal therapy, including combined hormonal contraceptives and progestin-only contraceptives, a post-hoc analysis of the pivotal EINSTEIN-DVT and -PE study showed a comparable risk of recurrent thrombosis among women using and not using hormonal therapy during the anticoagulant period. 5 This observation further supports the feasibility of continued combined hormonal contraceptives in conjunction with anticoagulation therapy. However, of paramount importance is the recognition that adequate anticoagulant therapy is required for the safe use of combined hormonal contraceptives and that these agents should be discontinued before anticoagulation withdrawal. 3 Financial Disclosure: The authors did not report any potential conflicts of interest.
In Reply:
We thank Drs. Rottenstreich, Bauman, and Kalish for their thoughtful letter in response to our Clinical Conundrum piece regarding contraceptive choice in a patient who has abnormal vaginal bleeding while taking anticoagulation therapy. 1 We appreciate their expertise in hematology and acknowledge that their familiarity with anticoagulation therapy is superior to our own. Our goal in this piece was to give evidence-based practical advice for a relatively common, complicated clinical scenario. Although we did mention rivaroxaban as an example of a direct Factor Xa inhibitor, we did not mean to imply it was the only direct-acting oral anticoagulant with this side effect. We also mention that decreasing anticoagulant dosing is a potential option for management of abnormal uterine bleeding for patients on anticoagulation therapy, but in practice have found that both hematologists and gynecologists are unwilling to risk the small potential increased possibility of thromboembolic events. We too referenced the Martinelli article 2 and acknowledge the lack of evidence for advising against the use of combined hormonal contraception in women who are actively receiving therapeutic anticoagulation treatment, as advised by the World Health Organization. However, similar to anticoagulant dose reduction, we have found that physicians are unwilling to assume the potential risk of clotting despite evidence to the contrary. Copyright ª by The American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc.
Unauthorized reproduction of this article is prohibited. 
